1. Home
  2. NCT vs DBVT Comparison

NCT vs DBVT Comparison

Compare NCT & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCT
  • DBVT
  • Stock Information
  • Founded
  • NCT 2011
  • DBVT 2002
  • Country
  • NCT Hong Kong
  • DBVT France
  • Employees
  • NCT N/A
  • DBVT N/A
  • Industry
  • NCT
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NCT
  • DBVT Health Care
  • Exchange
  • NCT NYSE
  • DBVT Nasdaq
  • Market Cap
  • NCT 115.5M
  • DBVT 102.0M
  • IPO Year
  • NCT 2025
  • DBVT N/A
  • Fundamental
  • Price
  • NCT $3.48
  • DBVT $9.83
  • Analyst Decision
  • NCT
  • DBVT Strong Buy
  • Analyst Count
  • NCT 0
  • DBVT 3
  • Target Price
  • NCT N/A
  • DBVT $13.67
  • AVG Volume (30 Days)
  • NCT 157.2K
  • DBVT 83.0K
  • Earning Date
  • NCT 01-01-0001
  • DBVT 04-30-2025
  • Dividend Yield
  • NCT N/A
  • DBVT N/A
  • EPS Growth
  • NCT N/A
  • DBVT N/A
  • EPS
  • NCT 0.13
  • DBVT N/A
  • Revenue
  • NCT $25,526,936.00
  • DBVT $3,497,000.00
  • Revenue This Year
  • NCT N/A
  • DBVT $1,700.53
  • Revenue Next Year
  • NCT N/A
  • DBVT $535.67
  • P/E Ratio
  • NCT $26.26
  • DBVT N/A
  • Revenue Growth
  • NCT N/A
  • DBVT N/A
  • 52 Week Low
  • NCT $3.29
  • DBVT $0.44
  • 52 Week High
  • NCT $8.76
  • DBVT $9.90
  • Technical
  • Relative Strength Index (RSI)
  • NCT N/A
  • DBVT 68.26
  • Support Level
  • NCT N/A
  • DBVT $9.18
  • Resistance Level
  • NCT N/A
  • DBVT $10.12
  • Average True Range (ATR)
  • NCT 0.00
  • DBVT 0.74
  • MACD
  • NCT 0.00
  • DBVT -0.01
  • Stochastic Oscillator
  • NCT 0.00
  • DBVT 84.32

About NCT INTERCONT (CAYMAN) LIMITED

Intercont (Cayman) Ltd operates through its subsidiaries. It is principally engaged in the time charter service and vessel management services business.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Share on Social Networks: